Eli Lilly CEO Lechleiter to Retire After Eight-Year Stint

July 27, 2016 | After eight years at the helm of Eli Lilly, a tenure characterized by a steadfast belief in home-grown research, rather than deals, John Lechleiter is retiring. David Ricks, who currently runs Lilly's diversified bio-medicines unit-which develops drugs for neurological and cardiovascular disorders, among other diseases-will be named CEO on Jan. 1 Xconomy